BIOVENTUS INC. - CLASS

Bioventus Reports Second Quarter Results; Updates Full-Year 2022 Financial Guidance

11 Aug 2022 07:00:03 By Nasdaq GlobeNewswire

Bioventus Receives FDA 510(k) Clearance for SonaStar Elite  

03 Aug 2022 07:00:02 By Nasdaq GlobeNewswire

Bioventus to Report Second Quarter of Fiscal Year 2022 Financial Results on August 11, 2022

26 Jul 2022 07:00:00 By Nasdaq GlobeNewswire

Bioventus Completes CartiHeal Acquisition

12 Jul 2022 08:30:00 By Nasdaq GlobeNewswire

Bioventus Amends CartiHeal Acquisition Structure

21 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Bioventus Reports First Quarter Results; Reaffirms Full-Year 2022 Financial Guidance

10 May 2022 07:00:04 By Nasdaq GlobeNewswire

Bioventus Cancels Proposed $415 Million Offering of Senior Notes; Reaffirms Full-Year 2022 Financial Guidance

03 May 2022 17:47:17 By Nasdaq GlobeNewswire

Bioventus Agrees to Nationwide Contract with Cigna Commercial Plans for DUROLANE® and GELSYN-3® for Knee Osteoarthritis

02 May 2022 07:00:01 By Nasdaq GlobeNewswire

Bioventus Announces Preliminary First Quarter Net Sales and Adjusted EBITDA

26 Apr 2022 09:05:09 By Nasdaq GlobeNewswire

Bioventus Announces $415 Million Offering of Senior Notes

26 Apr 2022 08:38:49 By Nasdaq GlobeNewswire

Bioventus to Report First Quarter of Fiscal Year 2022 Financial Results on May 10, 2022

25 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Bioventus TheraSkin Coverage Expands to Provide for 17 Million More Covered Lives

08 Apr 2022 09:15:08 By Nasdaq GlobeNewswire

Bioventus Announces Inducement Equity to SVP Chief Financial Officer Mark Singleton

05 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Bioventus Exercises Call Option to Acquire CartiHeal

04 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

Bioventus to Present at the Canaccord Genuity Musculoskeletal Conference

16 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

Bioventus Reports Fourth Quarter and Full Year 2021 Financial Results; Introduces Full Year 2022 Financial Guidance

10 Mar 2022 07:00:03 By Nasdaq GlobeNewswire

Bioventus Receives 510(k) Clearance for StimRouter Pain Management Device

01 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Bioventus Appoints Mark Singleton as Chief Financial Officer

28 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

Bioventus to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 10, 2022

22 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Bioventus Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue

11 Jan 2022 07:00:00 By Nasdaq GlobeNewswire